Ads
related to: mantle cell non-hodgkin's lymphoma- Download Brochure
Get Info On A R/R MCL Treatment
Option With A Downloadable PDF
- Patient Support
See How Cell Therapy May Treat MCL
With Info For Patients & Caregivers
- MCL Treatment Option
Learn About Mantle Cell Lymphoma
And Explore A Treatment Option
- Safety & Side Effects
Read Important Safety Information
Along With Possible Side Effects
- Download Brochure
Search results
Results from the WOW.Com Content Network
Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, comprising about 6% of cases. [ 1 ] [ 2 ] It is named for the mantle zone of the lymph nodes where it develops. [ 3 ] [ 4 ] The term 'mantle cell lymphoma' was first adopted by Raffeld and Jaffe in 1991.
Non-Hodgkin lymphoma (NHL), also known as non-Hodgkin's lymphoma, is a group of blood cancers that includes all types of lymphomas except Hodgkin lymphomas. [1] Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and tiredness. [1] Other symptoms may include bone pain, chest pain, or itchiness. [1]
Four chimeric antigen receptor T cell therapies are FDA-approved for non-Hodgkin lymphoma, including lisocabtagene maraleucel (for relapsed or refractory large B-cell lymphoma with two failed systemic treatments), axicabtagene ciloleucel, tisagenlecleucel (for large B-cell lymphoma), and brexucabtagene autoleucel (for mantle cell lymphoma ...
Aggressive lymphoma, also known as high-grade lymphoma, is a group of fast growing non-Hodgkin lymphoma. [1]There are several subtypes of aggressive lymphoma. These include AIDS-associated lymphoma, angioimmunoblastic lymphoma, Burkitt lymphoma, central nervous system (CNS) lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and peripheral T-cell lymphoma. [1]
FL is the most prevalent form of indolent lymphoma, accounting for 70% of indolent cases and 20–30% of all non-Hodgkin lymphoma cases, with a yearly incidence of 1.6 to 3.1 per 100,000. [13] [15] It is most frequently diagnosed among people in their 50s and 60s, and is more common among white populations than black or Asian populations. [14]
The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma. Previous to IPI's development, the primary consideration in assessing prognosis was the Ann Arbor stage alone, but this was increasingly found to be an inadequate means of ...
Primary gastric lymphoma (lymphoma that originates in the stomach itself) [1] is an uncommon condition, accounting for less than 15% of gastric malignancies and about 2% of all lymphomas. However, the stomach is a very common extranodal site for lymphomas (lymphomas originate elsewhere and metastasise to the stomach). [ 2 ]
In situ lymphoid neoplasia (ISLN, also termed in situ lymphoma) is a precancerous condition newly classified by the World Health Organization in 2016. The Organization recognized two subtypes of ISLN: in situ follicular neoplasia (ISFN) and in situ mantle cell neoplasia (ISMCL). [1]
Ads
related to: mantle cell non-hodgkin's lymphoma